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Abstract
Background: Candidate biomarkers have been identified for clear cell renal cell carcinoma
(ccRCC) patients, but most have not been validated.
Objective: To validate published ccRCC prognostic biomarkers in an independent patient
cohort and to assess intratumour heterogeneity (ITH) of the most promising markers to guide
biomarker optimisation.
Design, setting, and participants: Cancer-speciﬁc survival (CSS) for each of 28 identiﬁed
genetic or transcriptomic biomarkers was assessed in 350 ccRCC patients. ITH was interro-
gated in a multiregion biopsy data set of 10 ccRCCs.
Outcome measurements and statistical analysis: Biomarker association with CSS was ana-
lysed by univariate and multivariate analyses.
Results and limitations: A total of 17 of 28 biomarkers (TP53 mutations; ampliﬁcations of
chromosomes 8q, 12, 20q11.21q13.32, and 20 and deletions of 4p, 9p, 9p21.3p24.1, and 22q;
low EDNRB and TSPAN7 expression and six gene expression signatures) were validated as
predictors of poor CSS in univariate analysis. Tumour stage and the ccB expression signature
were the only independent predictors in multivariate analysis. ITH of the ccB signature was
identiﬁed in 8 of 10 tumours. Several genetic alterations that were signiﬁcant in univariate
analysis were enriched, and chromosomal instability indices were increased in samples
expressing the ccB signature. The study may be underpowered to validate low-prevalence
biomarkers.
Conclusions: The ccB signature was the only independent prognostic biomarker. Enrich-
ment of multiple poor prognosis genetic alterations in ccB samples indicated that several
events may be required to establish this aggressive phenotype, catalysed in some tumours
by chromosomal instability. Multiregion assessment may improve the precision of this
biomarker.
Patient summary: We evaluated the ability of published biomarkers to predict the survival of
patients with clear cell kidney cancer in an independent patient cohort. Only one molecular
test adds prognostic information to routine clinical assessments. This marker showed good
and poor prognosis results within most individual cancers. Future biomarkers need to
consider variation within tumours to improve accuracy.
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The clinical behaviour of clear cell renal cell carcinomas
(ccRCCs) is highly variable, ranging from slow-growing
localised tumours to aggressive metastatic disease. Thus
prognostic markers are important to guide therapeutic
intervention and follow-up strategies. Prognostic markers in
routine clinical use include tumour stage and grade and
prognostic models and nomograms that can also incorporate
necrosis, blood tests such as lactate dehydrogenase, haemo-
globin, platelets, and calcium levels, prior nephrectomy,
symptoms, and performance status [1–6]. However, the
accuracy of predictions remains limited for individual patients.
Molecular ccRCC characteristics including genetic altera-
tions and gene expression profiles have been identified as
potential novel prognostic biomarkers, but most of these
have not been independently validated. Even those that
have been validated have not entered clinical practice.
Neither have these biomarkers been compared with each
other to identify lead candidates for further development.
The analysis of multiple tumour regions from individual
ccRCCs recently identified substantial intratumour heteroge-
neity (ITH). Spatially separated subclones harbouring distinct
driver mutations and somatic copy number aberrations
(SCNAs) were present within primary tumours and between
primary tumours and metastases [7–9]. Phylogenetic recon-
struction revealed branched evolution, demonstrating that
multiple subclones were evolving simultaneously within
individual tumours. Assessment of a validated prognostic
gene expression signature [10] showed expression of the
good prognosis ccA signature or poor prognosis ccB signature
in different tumour regions within the same patient [7]. Thus
ITH with spatially separated subclones can lead to sampling
biases that may contribute to the lack of clinically qualified
biomarkers in ccRCC. Such observations raise questions
regarding how biomarker discovery strategies can be
improved in heterogeneous tumours.
We identified genetic and transcriptomic prognostic
biomarkers through a literature search to independently
validate them inThe CancerGenomeAtlas (TCGA) consortium
cohort of 350 ccRCC patients [11]. Independent predictors of
cancer-specific survival (CSS) were identified in multivariate
analysis, and the impact of ITH was assessed.
2. Methods
2.1. Literature search
Published genetic or transcriptomic prognostic biomarkers for RCC
patients were identiﬁed in PubMed and Google Scholar. Keywords
included biomarker, prognosis, and renal cell carcinoma. Literature cited in
review articles was also assessed. Publications had to be in the English
language. Studies exclusively based on non–clear cell histology were
excluded. Details of publications excluded for technical reasons can be
found in the Supplement.
2.2. Validation cohort
Somatic mutation (n = 417) and clinical data (n = 446) were obtained
from [11]. Single nucleotide polymorphism (SNP) array (n = 450) andRNA sequencing (RNA-seq) data (n = 469) for the same cohort were
downloaded (https://tcga-data.nci.nih.gov/tcga/) on March 14, 2012,
and September 18, 2012, respectively. Themolecular and clinical data for
our analysis were available for 350 of these patients. We used our
previously published multiregion gene expression data sets GSE31610
and GSE3000 [7,8] for the assessment of ITH (data sets available at
http://www.ncbi.nlm.nih.gov/geo/). Data processing is described in the
Supplement.
2.3. Statistical analysis
CSS was assessed by the Kaplan-Meier method from the initial
pathologic diagnosis to death with tumour as the end point. Statistical
signiﬁcance was assessed with the log-rank test. Hazard ratios (HRs)
were calculated using univariate Cox regression analysis. Competing risk
analysis was performed using death with tumour as the end point and
death without tumour as the competing risk event. Variables with
p  0.05 were included into multivariate Cox regression analysis with
backwards stepwise selection.
Differences in enrichment of genetic aberrations and genomic
instability indices in ccA and ccB subgroups were assessed by the
Fisher exact test and the Wilcoxon test, respectively. Details of the
statistical analysis are provided in the Supplement.
3. Results
3.1. Identification of prognostic biomarkers
The literature search identified 30 publications describing
RCC prognostic genetic or gene expression markers. Three
multigene expression signatures with < 70% of probes
mapping to genes annotated in the TCGA RNA-seq data
set and one signature based on a mathematical model
optimised for array expression data and not readily
applicable to RNA-seq data were excluded. Overall, 28
candidate biomarkers were identified from the remaining
26 publications for validation (Table 1).
3.2. Biomarker validation by univariate analysis
The median follow-up of the validation cohort was 51 mo.
Clinical/pathologic characteristics (Table 2) were similar to
the RCC cohorts in which the candidate biomarkers had
been identified (Supplemental Table 1). All patients had
undergone nephrectomy from which the samples for
molecular analysis had been taken. Higher tumour stage
and grade were significantly associated with poor CSS
(Table 3 and Fig. 1) as expected. Other established clinical
prognostic variables such as blood test results, performance
status, or necrosis were not available for all patients and
were not evaluated. A total of 19 of 28 molecular
biomarkers were significantly associated (p  0.05) with
CSS (Table 3).
3.2.1. Somatic mutations
Mutations in five driver genes were described as potential
prognostic markers [11–18], but only nonsynonymous
mutations in the BRCA1 associated protein-1 (ubiquitin
carboxy-terminal hydrolase) (BAP1) (HR: 1.94; p = 0.022)
and tumour protein 53 (TP53) (HR: 5.09; p < 0.001) tumour
suppressor genes were validated as predictors of poor CSS
Table 1 – Candidate prognostic biomarkers identified in the literature search
Variable Prognosis Analysis Cohort size* (n) Reference
Somatic mutations
VHL (loss of function+
mutations)
Poor (OS/PFS) Sequencing 56 Kim et al. [12]
VHL (loss of function+
mutations)
Poor (CSS) Sequencing 83 Schraml et al. [13]
VHL (somatic
mutations)
Better (CSS/CFS) Sequencing 134 Yao et al. [14]
PBRM1 Better (OS) Sequencing 145 + 327 Kapur et al. [15]
BAP1 Poor (OS) Sequencing 145 + 327 Kapur et al. [15]
BAP1 Poor (CSS) Sequencing 188 + 421 Hakimi et al. [16]
BAP1 Poor (OS) Sequencing >400 TCGA consortium [11]
BAP1 Poor (OS) Sequencing 240 Sato et al. [17]
SETD2 Poor (CSS) Sequencing 188 + 421 Hakimi et al. [16]
SETD2 Poor (CFS) Sequencing 240 Sato et al. [17]
TP53 Poor (CSS) Sequencing 416 Kandoth et al. [18]
Somatic copy number variations
5q31-qter (5q focal)
Ampliﬁcation
Better (CSS) Cytogenetics 104 Gunawan et al. [19]
7q36.2 (7q focal)
Ampliﬁcation
Poor (CSS) Array CGH, FISH 53 Sanjmyatav et al. [20]
8q Ampliﬁcation Poor (CSS) Cytogenetics 336 Klatte et al. [21]
8q Ampliﬁcation Poor (OS) SNP array 85 Monzon et al. [22]
12 Ampliﬁcation Poor (RFS) Cytogenetics 50 Elfving et al. [25]
20q11.21q13.32
(20q focal)
Ampliﬁcation
Poor (CSS) Array CGH, FISH 53 Sanjmyatav et al. [20]
20 Ampliﬁcation Poor (RFS) Cytogenetics 50 Elfving et al. [25]
3p Deletion Better (CSS) Cytogenetics 246 Klatte et al. [23]
3p Deletion Better (CSS) Cytogenetics 288 Kroeger et al. [24]
4p Deletion Poor (CSS) Cytogenetics 246 Klatte et al. [23]
8p Deletion Poor (RFS) Cytogenetics 50 Elfving et al. [25]
9p21.3p24.1
(9p focal)
Deletion
Poor (CSS) CGH, FISH 53 Sanjmyatav et al. [20]
9p Deletion Poor (CSS) Cytogenetics 246 Klatte et al. [23]
9p Deletion Poor (CSS/RFS) Cytogenetics, FISH 703 La Rochelle et al. [26]
9p Deletion Poor (RFS) CGH 37 Moch et al. [27]
9p Deletion Poor (CSS) FISH 73 Brunelli et al. [28]
14q Deletion Poor (CSS) Cytogenetics 246 Klatte et al. [23]
14q Deletion Poor (CSS) Cytogenetics 288 Kroeger et al. [24]
14q Deletion Poor (OS/RFS) SNP array 85 Monzon et al. [22]
19 Deletion Poor (CSS) Cytogenetics 131 Antonelli et al. [29]
22 Deletion Poor (CSS) Cytogenetics 131 Antonelli et al. [29]
Gene expression analysis
CD31, EDNRB, and
TSPAN7 expression
levels
Higher expression
levels of each are
better (CSS)
mRNA arrays 24 Wuttig et al. [30]
Aggressive and
nonaggressive
ccRCCs classiﬁed
using 35 genes
(26 [74%] genes
assessed in current
study)
Aggressive worse
than nonaggressive
(CSS)
mRNA arrays 66 Kosari et al. [31]
Two gene expression
clusters classiﬁed
using 259 genes
(220 [85%] genes
assessed in current
study)
Cluster 2 worse
than cluster 1 (CSS)
mRNA arrays 177 Zhao et al. [33]
Indolent and aggressive
ccRCC classiﬁed using
44 genes (36 [82%]
genes assessed in
current study)
Aggressive worse
than indolent
cDNA arrays 38 Lane et al. [32]
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ccA/ccB subgroup
classiﬁed using
110 genes (103 [94%]
genes assessed in
current study)
ccB worse than
ccA (CSS)
mRNA arrays 48 + 177 Brannon et al. [10]
Cluster A, B, and C classiﬁed
using 48 (B vs A/C) and
23 (A vs C) genes,
respectively (37 [77%]
and 21 [91%] genes,
respectively, assessed
in current study)
Cluster A better than B
and C, with C having the
poorest prognosis (CSS)
mRNA arrays 176 Beleut et al. [34]
TGFb signature:scored
with a panel of 157 TGFb
genes (145 [92%] genes
assessed in current study)
Poor for higher
expression (CSS)
mRNA arrays 176 Bostro¨m et al. [35]
CSS = cancer-speciﬁc survival; mRNA = messenger RNA; OS = overall survival; PFS = progression-free survival; SNP = single nucleotide polymorphism;
TGF = tumour growth factor.
* The cohort size in this table signiﬁes the number of cases for which follow-up data was available.
+ Loss of function mutation was deﬁned as frameshift or nonsense mutations.
Table 1 – (Continued)
Variable
Prognosis
Analysis
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patients with nonsynonymous mutations in polybromo 1
(PBRM1), SET domain containing 2 (SETD2), or von Hippel-
Lindau tumour suppressor, E3 ubiquitin protein ligase
(VHL) (Supplemental Fig. 1). Restricting the analysis to
VHL loss-of-function mutations (frameshift and nonsenseTable 2 – Patient and tumour characteristics of the validation
cohort
Variable TCGA cohort (n = 350)
Age, yr
Median (IQR) 61 (52–70)
Gender (%)
Male 222 (63)
Female 128 (37)
Fuhrman grade (%)
G1 4 (1)
G2 145 (41)
G3 146 (42)
G4 55 (16)
Clinical stage (%)
Stage I 162 (46)
Stage II 34 (10)
Stage III 96 (27)
Stage IV 58 (17)
Primary tumour spread (%)
T1 166 (48)
T2 40 (11)
T3 139 (40)
T4 5 (1)
Metastatic spread (%)
M0 293 (84)
M1 57 (16)
Lymph node spread (%)
N0 168 (48)
N1 8 (2)
NX (Undetermined) 174 (50)
Median follow-up 51 mo
Total no. of deaths 121
No. of deaths from ccRCC 80
ccRCC = clear cell renal cell carcinoma; TCGA = The Cancer Genome Atlas.mutations) in accordance with Kim et al. [12] and Schraml
et al. [13] or to stage I–III cases only [14] did not change the
results.
3.2.2. Somatic copy number alterations
Four focal SCNAs [19,20], six arm-level alterations [21–28],
and four whole chromosome alterations [25,29] have been
identified as candidate biomarkers. Several of these
SCNAs have been identified by cytogenetic and other
low-resolution analyses. Copy number profiles generated
from high-resolution SNP array data from TCGA was
converted into lower resolution cytoband-level data to
facilitate comparison. Amplification or deletion of 50% of
a chromosome arm or of both arms of a chromosome was
considered to be equivalent to an arm-level alteration as
described [11] or to a whole chromosome aberration,
respectively.
Nine of 14 unique SCNAs were validated as poor
prognostic markers. Chromosome 8q (Chrom8q) amplifica-
tion (HR: 2.70; p < 0.001), Chrom12 amplification (HR:
1.74; p = 0.034), Chrom20 focal amplification (HR: 2.44;
p < 0.001), Chrom20 amplification (HR: 2.37; p < 0.001),
Chrom4p deletion (HR: 1.97; p = 0.019), Chrom9p focal
deletion (HR: 2.33; p < 0.001), Chrom9p deletion (HR: 2.56;
p < 0.001), Chrom19 deletion (HR 3.25; p = 0.034), and
Chrom22q deletion (HR: 2.23; p = 0.012) were significantly
associated with poor CSS (Fig. 1 and Table 3). The remaining
five SCNA markers failed validation (Supplemental Fig. 1).
3.2.3. Gene expression analysis
EDNRB and TSPAN7 gene expression above defined cut-offs
[30] correlatedwith better CSS (HR: 0.37; p < 0.001 and HR:
0.29; p < 0.001, respectively), but CD31 overexpression was
not significant. Non-negative matrix factorisation (NMF)
clustering was applied for each multigene expression
signature [10,31–34] to identify samples with distinct
expression profiles (Supplemental Fig. 2). All prognostic
Table 3 – Univariate survival analysis
Variable No. of cases (n = 350) (%) HR (95% CI) p value
Clinical and pathologic characteristics
Stage II vs stage I 34 (10) 4.45 (1.55–12.77) 0.006
Stage III vs stage I 96 (27) 7.34 (3.16–17.08) <0.001
Stage IV vs stage I 58 (17) 25.24 (11.26–56.71) <0.001
G3 vs G1/G2 146 (42) 2.35 (1.30–4.26) 0.005
G4 vs G1/G2 55 (16) 7.43 (3.99–13.81) <0.001
Somatic mutations
VHL loss of function mutation 86 (24.5) 0.59 (0.34–1.04) 0.064
VHL nonsyn mutation (all
cases)
178 (51) 0.80 (0.51–1.25) 0.323
VHL nonsyn mutations (stage
I–III cases)
155/292 (53) 0.95 (0.50–1.80) 0.873
PBRM1 nonsyn mutation 117 (33) 0.90 (0.56–1.43) 0.643
BAP1 nonsyn mutation 37 (10.5) 1.94 (1.08–3.45) 0.022
SETD2 nonsyn mutation 39 (11) 1.41 (0.76–2.60) 0.273
TP53 nonsyn mutation 7 (2) 5.09 (1.85–14.00) <0.001
Somatic copy number variations
5q focal ampliﬁcation 191 (54.5) 0.72 (0.47–1.12) 0.143
7q focal ampliﬁcation 95 (27) 1.29 (0.81–2.05) 0.283
8q ampliﬁcation 33 (9) 2.70 (1.52–4.81) <0.001
12 ampliﬁcation 56 (16) 1.74 (1.04–2.91) 0.034
20q focal ampliﬁcation 51 (15) 2.44 (1.49–3.99) <0.001
20 ampliﬁcation 47 (13) 2.37 (1.41–3.97) <0.001
3p deletion 318 (91) 0.86 (0.41–1.79) 0.687
4p deletion 42 (12) 1.97 (1.10–3.52) 0.019
8p deletion 101 (29) 1.58 (0.99–2.50) 0.051
9p focal deletion 85 (24) 2.33 (1.49–3.64) <0.001
9p deletion 88 (25) 2.56 (1.64–3.99) <0.001
14q deletion 140 (40) 1.51 (0.97–2.35) 0.064
19 deletion 6 (1.7) 3.25 (1.02–10.32) 0.034
22q deletion 26 (7) 2.23 (1.18–4.23) 0.012
Gene expression analysis
CD31 expression
< median 175 (50) 0.64 (0.41–1.01) 0.051
 median 175 (50)
EDNRB expression
< median 175 (50) 0.37 (0.23–0.59) <0.001
 median 175 (50)
TSPAN7 expression
<33 percentile 105 (30) 0.29 (0.18–0.45) <0.001
33 percentile 245 (70)
Kosari signature
Nonaggressive 242 (69) 2.85 (1.84–4.43) <0.001
Aggressive 108 (31)
Zhao signature
Cluster 1 (good) 269 (77) 5.26 (3.37–8.22)
Cluster 2 (poor) 81 (23) <0.001
Lane signature
Indolent 219 (63) 4.21 (2.62–6.77) <0.001
Aggressive 131 (37)
ccA/ccB status
ccA 240 (69) 4.90 (3.09–7.76) <0.001
ccB 110 (31)
Beulet signature
Cluster A 127 (36) 1.00 (Ref) 0.005
Cluster B 175 (50) 2.27 (1.31–3.96)
Cluster C 48 (14) 2.30 (1.13–4.66)
TGFb signature
Low expression score 175 (50) 1.98 (1.23–3.16) 0.003
High expression score 175 (50)
CI = conﬁdence interval; HR = hazard ratio; nonsyn = nonsynonymous; TGF = tumour growth factor.
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[(Fig._1)TD$FIG]
Fig. 1 – Kaplan-Meier survival estimates for cancer-specific survival for clinical and genetic markers: (A) tumour stage; (B) Fuhrman grade; (C) BAP1
nonsynonymous (nonsyn) mutation status; (D) TP53 nonsyn mutation status; (E) chromosome (Chrom) 8q amplification (amp) status; (F) Chrom12
amp status; (G) Chrom20q focal amp status; (H) Chrom20 amp status; (I) Chrom4p deletion (del) status; (J) Chrom9p focal del status; (K) Chrom9p del
status; (L) Chrom19 del status; (M) Chrom22q del status.
WT = wild type.
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Fig. 2 – Kaplan-Meier survival estimates for cancer-specific survival for gene expression markers: (A) EDNRB expression levels; (B) TSPAN7 expression
levels; (C) gene expression subgroup of patients, Kosari signature; (D) gene expression subgroup of patients, Zhao signature; (E) gene expression
subgroup of patients, Lane signature; (F) gene expression subgroup of patients, ccA/ccB; (G) gene expression subgroup of patients, Beleut signature; (H)
gene expression subgroup of patients according to tumour growth factor (TGF) b activity score.
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 9 3 6 – 9 4 8942gene expression signatures validated: the aggressive
subgroup defined by Kosari [31] had worse CSS than the
nonaggressive subgroup (HR: 2.85; p < 0.001); the Zhao
[33] poor prognosis cluster 2 had worse CSS than cluster 1
(HR: 5.26; p < 0.001). The aggressive subgroup defined by
Lane et al. [32] showed worse CSS than the indolent
subgroup (HR: 4.21; p < 0.001); the Brannon [10] poor
prognosis ccB subgroup (HR: 4.90; p < 0.001) had worse
CSS than the ccA subgroup. Based on Beleut et al. [34], CSS
was significantly worse for patients in the poor prognosis
clusters C (HR: 2.21; p = 0.034) and B (HR: 2.46; p = 0.002)
than for those in cluster A, although CSS of clusters B and C
showed no significant difference. The poor-risk subgroup
of Bo¨strom et al. [35] with a high tumour growth factor b(TGF-b) score had worse CSS than the subgroup with a low
score (HR: 1.98; p = 0.003) (Fig. 2 and Table 3).
With the exception of BAP1 mutations and Chrom19
deletions, all markers that were significant in log-rank
analysis were also significant in a competing risk analysis
including death from causes other than cancer.
3.3. Identification of independent biomarkers in multivariate
analysis
Chrom9p focal deletion and Chrom20 whole arm amplifi-
cation were excluded because their HRs were lower than
the overlapping Chrom9p arm-level deletions and Chrom20
focal amplifications. The remaining 17 biomarkers that had
Table 4 – Multivariate survival analysis
Variable Including BAP1 mutations and
chromosome 19 deletion
Excluding BAP1 mutations and chromosome 19 deletion
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Tumour stage
Stage I 1.00 (Ref) 1.00 (Ref)
Stage II 3.48 (1.20–10.06) 0.022 3.40 (1.18–9.82) 0.024
Stage III 4.61 (1.93–11.00) <0.001 4.86 (2.05–11.55) <0.001
Stage IV 18.01 (7.89–41.12) <0.001 17.77 (7.79–40.53) <0.001
Chromosome 19 deletion 4.18 (1.27–13.69) 0.018 – –
ccA status 1.00 (Ref) 1.00 (Ref)
ccB status 2.99 (1.87–4.80) <0.001 2.95 (1.84–4.72) <0.001
CI = conﬁdence interval.
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together with tumour stage and grade into the multivariate
analysis (MVA). Tumour stage, the ccA/ccB gene expression
signature, and Chrom19 deletions were the only indepen-
dent predictors of CSS (Table 4 and Supplemental Table 2).
After exclusion of the two markers (BAP1 mutations,
Chrom19 deletions) that were not significant in the
competing risk analysis, only tumour stage and the ccA/
ccB signature remained significant in MVA (Table 4). Based
on these results and the small number of six tumours
showing Chrom19 deletions, the ccB signature was the lead
candidate for further assessment.
The ccB signature was consistently associated with a
worse prognosis in patients with stage I (HR > 10;
p < 0.001), stage II/III (HR: 3.03; p = 0.003), and stage IV
ccRCCs (HR: 2.15; p = 0.015) (Supplemental Fig. 3). A total of
135 patients with stage I tumours expressing the ccA
signature demonstrated particularly good outcomes with
no cancer-specific deaths for >6 yr. The ccA/ccB signature
was also significant in MVA when assessed together with
the validated and widely used size, stage, grade, and
necrosis (SSIGN) prognostic scoring system [4,36,37] (data
available for a subgroup of 334 patients; Supplemental
Table 3). CSS of patients whose tumours displayed the ccA
or ccB signature were significantly different in three of five
validated SSIGN score categories [36,37] (Supplemental Fig.
4). The ccA/ccB signature could not be compared with other
clinical nomograms [1,2,5,6] because essential parameters
were not available for most of the patients in the TCGA
cohort. After completion of our literature search, the
ClearCode34 prognostic expression signature was pub-
lished that is based on the ccA/ccB signature [38]. This
signaturewas significant in univariate analysis and together
with tumour stage in MVA if the ccA/ccB signature was
omitted (Supplemental Table 4). Although the HR for
ClearCode34 in the MVA was lower (HR: 2.23) than that of
the ccA/ccB signature (HR: 2.95), the implementation of this
34-gene signaturemay be easier in clinical practice than the
110-gene ccA/ccB signature.
3.4. Molecular drivers of the ccB subgroup
We next investigated whether the ccB expression signature
might reflect the transcriptomic impact of the poor-riskgenetic alterations that were significant in log-rank analysis
but failed in the multivariate analysis. Seven of nine poor
prognosis genetic alterations (BAP1 and TP53 mutations;
Chrom8q, Chrom12, and Chrom20q focal amplifications;
Chrom9p and Chrom22q deletions) were significantly
enriched ( p < 0.05) in the ccB subgroup (Fig. 3). Overall,
72% of the ccB samples showed at least one of these seven
aberrations compared with only 30% of ccA samples
(Fig. 4A). Both the maximum and the median number of
these aberrations per sample were higher in the ccB group
than in the ccA group (Fig. 4A and 4B). In contrast, only two
of the eight candidate genetic markers that had failed
univariate validation were enriched in ccB samples
(Supplemental Fig. 5), and the median number of these
aberrations between ccA and ccB samples was not
statistically different (Fig. 4C and 4D).
Chromosomal instability fosters the acquisition of SCNAs
and has been associated with poor prognosis in several
cancers [39]. To reveal whether enrichment of chromosomal
aberrations in ccB was a result of increased chromosomal
instability, we calculated the weighted Genomic Instability
Index (wGII), which is a measure of overall copy number
aberrations (wGII 0.2 is considered unstable [40]). The ccB
samples had significantly higher wGIIs compared with
ccA samples (p < 0.001; Fig. 4E). Based on these results, it
appears possible that the aggressive ccB phenotype is partially
driven by several poor prognosis SCNAs co-occurring within
these samples, permitted by a cancer genomic background
of elevated chromosomal instability.
3.5. Intratumour heterogeneity of the ccA/ccB signature
We previously found that the ccA and the ccB signatures
were present simultaneously within an individual ccRCC
[7]. To investigate whether this signature commonly
displays ITH, we reanalysed our published gene expression
data of 63 tumour regions from 10 stage II–IV ccRCCs [7,8]
(Supplemental Fig. 6) and mapped the results onto the
phylogenetic trees previously published for these tumours
[8] (Fig. 5). Only two tumours homogeneously expressed
the ccA signature; the other eight tumours were heteroge-
neous with ccA and ccB components detectable, suggesting
the need to sample multiple tumour regions to reliably
detect poor prognostic clones.
[(Fig._3)TD$FIG]
Fig. 3 – Heat map showing consensus non-negative matrix factorisation clustering analysis based on gene expression data of 103 ccA/ccB signature
genes. Patient assignment to ccA and ccB prognostic subgroups is indicated by coloured bars at the top of the heat map. Coloured bars below the heat
map depict the presence of poor prognosis genetic aberrations. The bar chart at the bottom of the figure represents the number of these genetic
aberrations per patient.
OR = odds ratio.
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A total of 17 of the 28 published genetic and transcriptomic
prognostic ccRCC markers were validated in log-rank
and competing risk analysis as predictors of CSS in this
independent validation cohort. Of those, only the ccB gene
expression signature was significant in MVA. Tumour stage
was the only other independent predictor of CSS in MVA.
Importantly, the ccA signature identified patients withstage I ccRCCs who had an excellent prognosis with no
cancer-specific deaths over >6 yr of follow-up. The ccA/ccB
signature was also significant in MVA with the established
SSIGN prediction model, demonstrating that this molecular
marker can add additional information to one of the
best currently available predictors based on clinical and
pathologic information. Thus the ccA/ccB signature could
refine personalised follow-up strategies or stratification
into adjuvant therapy trials. The novel ClearCode34
[(Fig._4)TD$FIG]
Fig. 4 – (A) Comparison of the number of poor prognosis genetic aberrations per sample between ccA and ccB subgroups. Only aberrations that are
enriched in the ccB subgroup were considered. (B) Box and whisker plot comparing median number of poor prognosis genetic aberrations between
samples assigned to the ccA and the ccB group. (Wilcoxon test; p < 0.001). (C) Comparison of the number of number of genetic aberrations that did not
pass univariate validation per sample between ccA and ccB subgroups. (D) Box plot and whisker plot showing the median number of genetic
aberrations that did not pass univariate validation between ccA and ccB subgroups (Wilcoxon test; p = 0.138). (E) Box plot and whisker plot comparing
weighted Genomic Instability Index (wGII) between ccA and ccB subgroups. wGII I0.2 is considered genomically unstable.
E U RO P E AN URO L OGY 6 6 ( 2 0 1 4 ) 9 3 6 – 9 4 8 945signature is based on the ccA/ccB signature but can be
assessed from 34 instead of 110 genes. The performance of
this new marker was slightly inferior, but it may neverthe-
less be valuable because clinical adoption may be easier.
Previous work revealed that genes overexpressed in
samples with the ccA signature are enriched for genes
implicated in angiogenesis and fatty acid, organic acid, and
pyruvate metabolism. Genes overexpressed in samples
displaying the ccB signature are enriched for cell differen-
tiation, epithelial to mesenchymal transition, mitotic cell
cycle, response to wounding, and TGF-b and Wnt signalling
genes [10]. We further revealed that seven of nine specific
genetic alterations that were validated in univariate
analysis were enriched in ccB samples with 72% of samples
harbouring at least one and up to six of these. These genetic
changes were only found in 30% of the ccA samples with amaximum of four aberrations per sample. Thus the ccB
signature may reflect the transcriptomic impact of these
poor prognosis alterations, but more than one alteration
may be necessary to establish this phenotype, and as yet
unknown alterations are also likely to contribute. Arguably,
prognostic markers are of limited clinical utility in ccRCC
due to the current absence of effective adjuvant strategies.
However, further study of the interplay of these genetic
aberrations and the pathways deregulated in the ccB
signature are clearly necessary to reveal the mechanisms
and biologic implications of the ccB phenotype. Such
insights could eventually foster the development of specific
therapeutic approaches for poor prognosis ccRCC.
Chromosomal instability indices (wGII) were higher in
ccB than in ccA samples, suggesting that chromosomal
instability may catalyse the evolution of the ccB phenotype
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Fig. 5 – Heterogeneity analysis of ccA/ccB expression profiles. The ccA or ccB profiles detected by consensus non-negative matrix factorisation clustering
in a multiregion analysis data set from 10 clear cell renal cell carcinomas were mapped onto the phylogenetic trees of these tumours (adapted with
permission from Nature Publishing Group [8]). Regional gene expression signatures were assigned to the dominant clones detected within the region.
The minority clones detected in some regions in the original publication were omitted.
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ground from which these SCNAs can be selected. These
results are hypothesis generating and will require further
study.
Evaluation of the ccA/ccB signature across multiple
tumour regions from each of 10 stage II–IV ccRCCs
demonstrated heterogeneous expression patterns with
ccA and ccB signatures coexisting in 8 of 10 cases. ITH
with spatial separation of subclones that may harbour
distinct transcriptomic profiles demonstrates that single
biopsies are unlikely to reveal a complete picture of the
landscape of even the best current binary classification
ccRCC biomarkers.These data suggest some interesting avenues for
research. Despite ITH, the ccB signature outperforms every
other candidate biomarker in this analysis. It is currently
unknown whether a tumour with a small ccB component
has a similarly poor prognosis to an identical size tumour
dominated by the ccB signature. If the absolute size of the
poor-risk clone, irrespective of the entire tumour popula-
tion, is the most critical parameter, then ITH may be less
problematic in small tumours because the chance of
analytical techniques sampling the high-risk cell population
would be high. However, detection of a poor-risk ccB clone
in larger tumours may be more difficult unless the entire
tumour is sampled or dominated by the ccB signature. These
E U RO P E AN URO L OGY 6 6 ( 2 0 1 4 ) 9 3 6 – 9 4 8 947considerations demonstrate that insights into the impact of
ITH on clinical outcomes are limited, raising important
questions regarding the clinical interpretation of subclonal
abundance and how heterogeneous tumours can be better
profiled for biomarker discovery and precision medicine.
Several candidate markers that failed validation in
univariate and multivariate analyses such as Chrom19
deletion, Chrom8q amplification, and BAP1 and TP53 muta-
tions had low prevalence 10%. This study is underpowered
to assess the role of these markers definitively. A further
limitation is the lack of protein expression data for the
validation cohort that precluded the inclusion of many
candidate biomarkers based on immunohistochemistry.
5. Conclusions
Taken together, this study suggests that the ccA/ccB gene
expression signature outperforms other transcriptomic and
genetic biomarkers for the prediction of ccRCC CSS and that
it adds prognostic information to tumour stage and to the
SSIGN prognostic model. This signature could be particu-
larly relevant for the profiling of stage I ccRCCs where the
detection of the ccA signature was associated with an
excellent prognosis. Stage I ccA tumours may only require
minimal follow-up, whereas ccB tumours may benefit from
more stringent surveillance and may be good candidates
for adjuvant therapy trials. Multiregion profiling of larger
cohorts could define how to integrate heterogeneity assess-
ments into biomarker predictions and further improve the
accuracy of the ccA/ccB signature.
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